The Biomolecules and Biomedicine is an international, peer-reviewed journal. Journal IF 2024: 2.2 Broad readership and scope. Open Access. Editorial Board.
The Biomolecules and Biomedicine (formerly, the Bosnian Journal of Basic Medical Sciences, BJBMS) is а premier venue for preclinical and clinical biomedical science discoveries. The journal was founded in 1998 and is published by the Association of Basic Medical Sciences, a nonprofit honor organization of physician-scientists. The Biomolecules and Biomedicine reaches readers across a wide range of
medical disciplines and sectors. The Journal publishes basic and translational/clinical research submissions and reviews in all biomedical specialties, including Genetics and Molecular biology, Immunology, Microbiology, Pathology, Biochemistry, Pharmacology, Anatomy, Biomaterials, New and Emerging Research and Diagnostic Methods, New and Emerging Medical Entities, and others. All research is available to the public for free. The Biomolecules and Biomedicine deposits published articles in PubMed Central, satisfying the NIH Public Access Policy and other similar funding agency requirements. Renowned international experts in the Journal's Editorial Board, together with external peer-reviewers, select the best submissions for publication. High visibility
Open Access: articles are freely available to readers immediately after publication. Highly accessed online content: more than 350,000 readers/month (100,000 at PubMed Central (April 2024); 120,000 at Journal's website (April 2024); more than 130,000 at Web of Science, Scopus, Google Scholar, and others). Newsletters: more than 20,000 registered users receive a newsletter tailored to their field of interest. Social media: articles are promoted through various social media channels (Twitter, LinkedIn, Facebook)
Advance online: all accepted articles are published Advance online and Ahead of print on PubMed within 3 days of acceptance, with citable DOIs, to make the article accessible as fast as possible. Print circulation: 200 copies of print issues are sent to major libraries, institutes, universities, conferences, and subscribers worldwide. BiomolBiomed Viewpoints: Journal's blog promotes authors and their research by publishing plain language summaries for a broad audience and media, as well as commentaries, interviews, news, and stories related to science and research. Indexing and abstracting
SCIE (Science Citation Index Expanded), Web of Science, Clarivate Analytics
JCR (Journal Citation Reports®), Clarivate Analytics
PubMed/MEDLINE (Biomol Biomed)
PubMed/MEDLINE (BJBMS)
PubMed Central (PMC)
SCOPUS
SJR (Scimago Journal and Country Rank) (BiomolBiomed)
SJR (Scimago Journal and Country Rank) (BJBMS)
DOAJ
SCILIT (BiomolBiomed)
SCILIT (BJBMS)
EBSCO
PROQUEST
Dimensions
Semantic Scholar
Google Scholar
EMBASE/Excerpta Medica
Europe PubMed Central
Medscape
ISSN Portal
ROAD
HINARI
CAS
X-MOL
CNKI
many libraries
Timely publication
The 2023 peer review performance metrics:
Number of submissions (2023): 1288
Average time from submission to initial decision (reject or peer review): 2 days
Average peer-review time and decision: 22 days
Average time from acceptance to advance online publication: 2 days
Average number of reviews received per manuscript: 4
Acceptance Rate: 15%
Meaningful metrics
The success of the articles published in BiomolBiomed is tracked in real-time by individualized Article-Level Metrics (Dimensions and PlumX). These reflect the viewership, download rates, social sharing, citations, field citation ratio, and relative citation ratio for each published article in real-time, and help you illustrate the impact of your research
Diabetes May Alter Immune Cell Patterns in Aortic Aneurysms
New histological findings suggest that type 2 diabetes may change how immune cells, particularly mast cells, are distributed within the aortic wall. This shift could reveal why diabetic patients show different patterns of vascular inflammation and aneurysm formation.
Could metabolic conditions redefine our understanding of aortic wall remodeling?
Discover how immune cell localization might shape future cardiovascular research:
Diabetes May Alter Immune Cell Patterns in Aortic Aneurysms, suggesting distinct inflammatory pathways and vascular remodeling mechanisms.
31/10/2025
Decitabine Suppresses Tumor Growth by Activating Mouse Mammary Tumor Virus and Interferon-β Pathways
In mice, a familiar cancer drug wakes up ancient “viral” DNA inside tumors, flips on the immune alarm interferon-beta, and slows growth—making cancer look infected to the immune system. The catch: that alarm can fade, pointing to smarter timing and promising pairings with checkpoint immunotherapy—worth a look for anyone curious about the next wave of cancer treatment.
Decitabine suppresses tumor growth by activating mouse mammary tumor virus and interferon-β pathways in mice; IRF7 wanes; supports checkpoint blockade.
29/10/2025
New Prognostic Model for Gastrointestinal Diffuse Large B-Cell Lymphoma Improves Survival Prediction
A new population-based study has developed the first dedicated nomogram for gastrointestinal DLBCL, outperforming traditional Ann Arbor staging in predicting long-term survival.
By integrating demographic, clinical, and social factors, this model brings us closer to truly individualized prognostication and treatment planning for this challenging lymphoma.
Read more about how this model reshapes precision oncology for GI-DLBCL:
New Prognostic Model for Gastrointestinal Diffuse Large B-Cell Lymphoma Improves Survival Prediction with precise, individualized risk assessment.
27/10/2025
Pre-Treatment Pan-Immune-Inflammation Value Predicts Prognosis in Limited-Stage Small-Cell Lung Cancer (Research Article)
Could inflammation predict how well lung cancer patients respond to therapy? Researchers found that the Pan-Immune-Inflammation Value, calculated from standard blood tests, correlates strongly with survival outcomes. This low-cost biomarker could become a valuable tool in tailoring care for SCLC patients.
ChatGPT said:Pre-Treatment Pan-Immune-Inflammation Value Predicts Prognosis in Limited-Stage Small-Cell Lung Cancer and helps identify high-risk patients.
24/10/2025
Frailty Linked to Poorer Survival in Renal Cell Carcinoma
(Meta-Analysis)
A recent study reveals a significant link between frailty and worse survival outcomes in renal cell carcinoma (RCC) patients. This finding underscores the importance of assessing frailty to improve treatment strategies and patient care. Learn how recognizing frailty could change the course of RCC management—whether for patients or healthcare providers.
Frailty linked to poorer survival in renal cell carcinoma, with evidence showing its significant impact on overall and progression-free survival outcomes.
22/10/2025
Lactate Improves Sepsis Mortality Prediction in ICU Patients
Sepsis remains one of the most formidable challenges in critical care, claiming countless lives each year despite medical advances. This new study highlights how a simple, routinely measured blood marker — lactate — can significantly enhance existing models for predicting sepsis outcomes.
Lactate Improves Sepsis Mortality Prediction in ICU Patients by enhancing NEWS and PIRO accuracy for early, precise risk assessment.
22/10/2025
Sepsis Sepsis remains a major challenge in intensive care units (ICUs) worldwide. It arises from a dysregulated immune response to infection that leads to life-threatening organ dysfunction. Despite modern treatments, mortality among ICU patients with sepsis remains high. As the authors state, “sepsis remains a global health problem with high morbidity and mortality.” Early identification and accurate assessment are crucial. Tools such as the National Early Warning Score (NEWS) and the Predisposition, Infection, Response, and Organ dysfunction (PIRO) model are widely used to predict outcomes, but their accuracy is limited....
Lactate Improves Sepsis Mortality Prediction in ICU Patients by enhancing NEWS and PIRO accuracy for early, precise risk assessment.
20/10/2025
𝘋𝘳𝘰𝘴𝘰𝘱𝘩𝘪𝘭𝘢 𝘮𝘦𝘭𝘢𝘯𝘰𝘨𝘢𝘴𝘵𝘦𝘳 Models for Inflammatory Bowel Disease: Mechanisms and Therapeutic Insights
Can a tiny fruit fly help us decode the complex pathology of inflammatory bowel disease?
Discover how 𝘋𝘳𝘰𝘴𝘰𝘱𝘩𝘪𝘭𝘢 𝘮𝘦𝘭𝘢𝘯𝘰𝘨𝘢𝘴𝘵𝘦𝘳 bridges gut inflammation, stem cell signaling, and translational therapeutics—offering fast, ethical, and genetically precise insights into IBD mechanisms.
Drosophila melanogaster Models for Inflammatory Bowel Disease: Mechanisms and Therapeutic Insights explore gut inflammation, pathways, and treatments.
17/10/2025
Serum Netrin-1, NSE, and S100β Predict Short-Term Outcomes in Sepsis-Associated Encephalopathy
Three routine blood markers—Netrin-1, NSE, and S100β—measured within 48 hours of sepsis clearly separated low- and high-risk encephalopathy.
Low Netrin-1 with high NSE/S100β strongly tracked 28-day mortality (combined AUC 0.983) using practical cutoffs: 114.4 ng/mL, 9.66 ng/mL, and 0.99 μg/mL.
See how this simple panel outperformed traditional scores and could sharpen early decision-making:
Serum Netrin-1, NSE, and S100β predict short-term outcomes in sepsis-associated encephalopathy by reflecting neuronal injury, inflammation, and disease severity.
15/10/2025
Blocking a Cell-Death Enzyme May Protect Hearing from Chemotherapy Damage
Cisplatin saves lives—but too often at the cost of a patient’s hearing. This new study reveals how targeting the DNA-repair enzyme PARP-1 can interrupt a destructive cell-death cascade in the inner ear—protecting auditory cells without blunting cisplatin’s anticancer power.
Blocking a cell-death enzyme may protect hearing from chemotherapy damage by preventing cisplatin-induced loss of inner-ear sensory cells.
13/10/2025
Weight Fluctuations Tied to Higher Dementia Risk, Meta-Analysis Shows
A large-scale meta-analysis of over 4.2 million participants reveals that individuals with the highest body weight variability have a 36% higher risk of developing dementia. This research offers a new perspective on how weight stability might reflect long-term brain health and metabolic balance.
Discover how consistent weight patterns could become an early indicator of dementia risk and what this means for prevention strategies in clinical and research settings.
Weight Fluctuations Tied to Higher Dementia Risk, Meta-Analysis Shows that greater body weight variability may increase dementia risk by 36%.
10/10/2025
SGLT2 Inhibitors Show Stronger Long-Term Blood Sugar Control Than Sulfonylureas
A new meta-analysis reveals that SGLT2 inhibitors provide stronger and more durable blood sugar control than sulfonylureas when added to metformin. The findings emphasize the value of long-term glycemic stability in guiding modern type 2 diabetes treatment strategies.
Be the first to know and let us send you an email when Biomolecules and Biomedicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
The BJBMS (Bosnian Journal of Basic Medical Sciences) is а premier venue for discoveries in basic and clinical biomedical science. The BJBMS was founded in 1998 and is published by the Association of Basic Medical Sciences, a nonprofit honor organization of physician-scientists.
Broad readership and scope. The BJBMS reaches readers across a wide range of medical disciplines and sectors. The journal publishes basic and translational/clinical research submissions and reviews in all biomedical specialties, including Genetics and Molecular biology, Immunology, Microbiology, Pathology, Biochemistry, Pharmacology, Anatomy, Biomaterials, new and emerging research and diagnostic methods, new and emerging medical entities, and others.
Open access. All research is available to the public for free. The BJBMS deposits published articles in PubMed Central, which satisfies the NIH Public Access Policy and other similar funding agency requirements.
Editorial Board. Renowned international experts in the journal's Editorial Board, together with external peer-reviewers select the best of the submissions for publication.
High visibility
Open Access: articles are freely available to readers immediately after publication.
Highly accessed online content: more than 150,000 visits/month (45,000 at PubMed Central (October 2019); 50,000 at Journal's website (March 2020); 45,000 at Web of Science, Scopus, Google Scholar, and others).
Newsletters: more than 9,000 registered users receive a newsletter tailored to their field of interest.
Social media: articles are promoted through various social media channels (Twitter, LinkedIn, Facebook)
Advanced online: all accepted articles are published Advanced online and Ahead of print on PubMed within 3 days of acceptance, with citable DOIs, to make the article accessible as fast as possible.
Print circulation: 300 copies of print issues are sent to major libraries, institutes, universities, conferences, and subscribers across the globe. Get the free sample copy here.
BJBMS Viewpoints: Journal's blog that promotes authors and their research by publishing plain language summaries for wide audience and media, as well as commentaries, interviews, news and stories related to science and research.
Indexing and abstracting
Science Citation Index Expanded (Web of Science, Clarivate Analytics)
Journal Citation Reports® (JCR)
PubMed/MEDLINE
PubMed Central (PMC)
SCOPUS
DOAJ
EBSCO
PROQUEST
Dimensions
Semantic Scholar
Google Scholar
EMBASE/Excerpta Medica
Europe PubMed Central
Medscape
ROAD
HINARI
CAS
many libraries
Timely publication
Time to First Editorial Decision (Rejection or Peer Review): 3 days
Time to First Decision after review (Rejection or Revision or Acceptance): 25 days
Time from Acceptance to Publication: 3 days (if no significant language editing is required)
Rejections without peer review: 40%
Acceptance Rate: 15%
Meaningful metrics
The success of the articles published in BJBMS is tracked in real-time by individualized Article-Level Metrics (Dimensions and PlumX). These reflect the viewership, download rates, social sharing, citations, field citation ratio, and relative citation ratio for each published article in a real-time, and help you illustrate the impact of your research
